Ubiquigent and Debiopharm enter agreement to support USP1 inhibitor programme for Debio 0432

Rel­ma­da Ther­a­peu­tics’ once-dai­ly REL-1017 has shown pos­i­tive da­ta in ma­jor de­pres­sive dis­or­der (MDD) from a reg­is­tra­tional Phase III tri­al, a year af­ter an un­ex­pect­ed late-stage

Mer­ck KGaA is al­lo­cat­ing over €300 mil­lion ($321.8 mil­lion) to build a new re­search build­ing at its head­quar­ters in Darm­stadt, Ger­many to study tech­nolo­gies for

A mammography screening decision aid with information about the benefits and harms of screening increased the percentage of average-risk women in their 40s who wanted